Delphia (USA)’s Guardant Health GH Stock Holding History

Delphia (USA)’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,984	Closed	-$201K	–	339
2022 Q2	$201K	Buy	+4,984	New	+$247K	0.14%	281

Other funds holding GH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Delphia (USA)'s GH Position: Q3 2022 in Review

Delphia (USA) sold out of Guardant Health (GH) in Q3 2022, closing a stake of 4,984 shares — an estimated $201K sold.

Delphia (USA) first reported a position in GH in Q2 2022 and held it in 1 quarter. The position peaked at $201K in Q2 2022. 328 funds tracked by Wall St. Rank hold GH as of Q3 2022.

Delphia (USA) reported no remaining Guardant Health position as of Q3 2022 after selling out during the quarter.
Delphia (USA) sold 4,984 Guardant Health shares in Q3 2022, an estimated $201K.
Delphia (USA) first reported a position in Guardant Health in Q2 2022 and held it in 1 quarter.
Delphia (USA)'s Guardant Health position peaked at $201K in Q2 2022.
328 funds tracked by Wall St. Rank held Guardant Health as of Q3 2022.

Based on Delphia (USA)'s 13F filing for Q3 2022, filed 14 Nov 2022.